• Big change for pain drugs   Friday, 22 Aug 2014 | 2:12 PM ET
    Big change for pain drugs

    CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."

  • Hot biotech drugs   Tuesday, 19 Aug 2014 | 7:07 AM ET
    Hot biotech drugs

    CNBC's Meg Tirrell reports which biotech drug developments investors are excited about.

  • Fighting obesity with Rxs   Monday, 18 Aug 2014 | 2:17 PM ET
    Fighting obesity with Rxs

    Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.

  • Red hot biotech stocks   Thursday, 14 Aug 2014 | 3:10 PM ET
    Red hot biotech stocks

    CNBC's Morgan Brennan runs through today's big biotech movers.

  • Time to buy biotech?   Wednesday, 13 Aug 2014 | 4:38 PM ET
    Time to buy biotech?

    Barbara Ryan, FTI Consulting, discusses the tremendous amount of innovation within in the biotech sector and why the segment is attractive.

  • Biotechs race for Ebola cure   Monday, 11 Aug 2014 | 5:30 PM ET
    Biotechs race for Ebola cure

    CNBC's Meg Tirrell looks at companies in the early stages of Ebola drug and vaccine trials.

  • Merck & Pfizer beat the Street   Tuesday, 29 Jul 2014 | 10:14 AM ET
    Merck & Pfizer beat the Street

    CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.

  • What's coming in biotech?   Wednesday, 23 Jul 2014 | 2:15 PM ET
    What's coming in biotech?

    "The market is very favorable for biotech these days," says Les Funtleyder, Bluecloud Healthcare, in discussing growth in the space.

  • Biogen CEO: Want to stop inversions? Reform tax code   Wednesday, 23 Jul 2014 | 11:45 AM ET
    Biogen CEO: Want to stop inversions? Reform tax code

    CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.

  • Faber Report: Puma Biotech surges   Wednesday, 23 Jul 2014 | 10:39 AM ET
    Faber Report: Puma Biotech surges

    CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.

  • Analyst calls out Yellen's biotech comments   Friday, 18 Jul 2014 | 12:45 PM ET
    Analyst calls out Yellen's biotech comments

    Mark Schoenbaum, ISI Group, explains why his views differ from Janet Yellen on whether the biotech sector is forming a bubble.

  • How will Yellen's comments impact US stocks?   Tuesday, 15 Jul 2014 | 11:34 PM ET
    How will Yellen's comments impact US stocks?

    Dodge Dorland, Chairman & Chief Investment Officer at Landor & Fuest Capital Managers, says social media and biotech stocks may see more downside in the short run.

  • Fed hits social, tech stocks   Tuesday, 15 Jul 2014 | 3:02 PM ET
    Fed hits social, tech stocks

    After Janet Yellen's comments on stretched valuations in the social media and biotech sectors, CNBC's Seema Mody looks at what stocks are taking the biggest hit.

  • Next global epidemic?   Tuesday, 15 Jul 2014 | 1:40 PM ET
    Next global epidemic?

    CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.

  • Acorda 'firmly on the side of research': CEO   Thursday, 10 Jul 2014 | 8:43 AM ET
    Acorda 'firmly on the side of research': CEO

    Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.

  • Biotech buys right now   Tuesday, 8 Jul 2014 | 5:46 PM ET
    Biotech buys right now

    The S&P Biotech ETF is down 7 percent this week. Robyn Karnauskas, Deutsche Bank biotechnology director, shares her large and small cap picks.

  • Rough day for biotech   Tuesday, 8 Jul 2014 | 1:06 PM ET
    Rough day for biotech

    CNBC's Meg Tirrell reports biotech stocks are performing lower than the broader markets.

  • Protect yourself from fake medicine   Monday, 7 Jul 2014 | 1:55 PM ET
    Protect yourself from fake medicine

    CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.

  • Incubating biotech's boom   Thursday, 3 Jul 2014 | 1:11 PM ET
    Incubating biotech's boom

    Quincy College in Massachusetts created a two year program to fill bio-manufacturing technician positions. CNBC's Mary Thompson reports how the school is fueling job growth.

  • Prescription drugs: Risk vs. cost   Wednesday, 2 Jul 2014 | 1:46 PM ET
    Prescription drugs: Risk vs. cost

    Due to the high cost of prescription drugs, many in the U.S. look overseas to save money. CNBC's Scott Cohn discusses if people are putting themselves at risk or beating big drug companies at their own game.